Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma

Journal of Surgical Oncology

Volumn 104, Issue 1, 2011, Pages 106-109

  Puig Costa, Manuel ^a,b   Oliveras Ferraros, Cristina ^b,c   Flaquer, Silvia ^b,c   Llopis Puigmarti, Francesca ^b,c   Pujol Amado, Eulalia ^b,c   Martin Castillo, Begoña ^b,c   Vazquez Martin, Alejandro ^b,c   Cufí, Sílvia ^b,c   Ortiz, Rosa ^a   Roig, Josep ^a,b   Codina Cazador, Antonio ^a,b   Menendez, Javier A ^b,c  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR MARKER;

CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GASTRECTOMY; GENETIC ENGINEERING AND GENE TECHNOLOGY; HUMAN; LETTER; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MICROARRAY; STOMACH CARCINOMA;

ANTIBODIES, IMMOBILIZED; BIOLOGICAL MARKERS; GENE EXPRESSION PROFILING; HUMANS; MATRIX METALLOPROTEINASES; PROTEIN ARRAY ANALYSIS; STOMACH NEOPLASMS;

EID: 79958087952     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21887     Document Type: Letter

References (21)

1. Herrmann K, Walch A, Balluff B, et al.: Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nat Clin Pract Gastroenterol Hepatol 2006;6:170-183.
2. Wagner AD, Moehler M: Development of targeted therapies in advanced gastric cancer: Promising exploratory steps in a new era. Curr Opin Oncol 2009;21:381-385.
3. Posadas EM, Simpkins F, Liotta LA, et al.: Proteomic analysis for the early detection and rational treatment of cancer - Realistic hope? Ann Oncol 2005;16:16-22. (Pubitemid 40124471)
4. Conrads TP, Hood BL, Petricoin EF III, et al.: Cancer proteomics: Many technologies, one goal. Expert Rev Proteomics 2005;2:693-703. (Pubitemid 41492391)
5. Wulfkuhle JD, Edmiston KH, Liotta LA, et al. Technology insight: Pharmacoproteomics for cancer - Promises of patienttailored medicine using protein microarrays. Nat Clin Pract Oncol 2006;3:256-268. (Pubitemid 43731111)
6. Gulmann C, Sheehan KM, Kay EW, et al.: Array-based proteomics: Mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 2006;208:595-606.
7. Borrebaeck CA, Wingren C: High-throughput proteomics using antibody microarrays: An update. Expert Rev Mol Diagn 2007;7:673-686. (Pubitemid 47547731)
8. Ellington AA, Kullo IJ, Bailey KR, et al. Antibody-based protein multiplex platforms: Technical and operational challenges. Clin Chem 2010;56:186-193.
9. Huang RP: An array of possibilities in cancer research using cytokine antibody arrays. Expert Rev Proteomics 2007;4:299-308.
10. Sier CF, Kubben FJ, Ganesh S, et al.: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413-417. (Pubitemid 26254571)
11. Joo YE, Seo KS, Kim HS, et al.: Expression of tissue inhibitors of metalloproteinases (TIMPs) in gastric cancer. Dig Dis Sci 2000;45:114-121. (Pubitemid 30111697)
12. Zhang S, Li L, Lin JY, et al. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 2003;9:899-904. (Pubitemid 36681652)
13. Koyama S: Enhanced cell surface expression of matrix metalloproteinases and their inhibitors, and tumor-induced host response in progression of human gastric carcinoma. Dig Dis Sci 2004;49:1621-1630.
14. Kubben FJ, Sier CF, van Duijn W, et al.: Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006;94:1035-1040.
15. Shim KN, Jung SA, Joo YH, et al. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol 2007;42: 120-128.
16. Seo YS, Park JJ, Kim JH, et al.: Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma. Dig Dis Sci 2007;52:753-759.
17. Bramhall SR, Hallissey MT, Whiting J, et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. Br J Cancer 2002;86:1864-1870.
18. Xue H, Lu B, Lai M: The cancer secretome: A reservoir of biomarkers. J Transl Med 2008;6:52.
19. Vazquez-Martin A, Colomer R, Menendez JA: Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature'in breast cancer. Eur J Cancer 2007;43:1117-1124. (Pubitemid 46590736)
20. Kulasingam V, Diamandis EP: Tissue culture-based breast cancer biomarker discovery platform. Int J Cancer 2008;123:2007-2012.
21. Rajcevic U, Niclou SP, Jimenez CR: Proteomics strategies for target identification and biomarker discovery in cancer. Front Biosci 2009;14:3292-3303.